logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12458667 B1

PDFFull Text
Date of Patent:
Nov. 04, 2025

Filed:

Dec. 30, 2024

Bispecific chimeric antigen receptors targeting cd20 and bcma

Applicant:

Abelzeta Inc., Rockville, MD (US);

Inventors:

Yihong Yao, Rockville, MD (US);

Jiaqi Huang, Rockville, MD (US);

Shigui Zhu, Rockville, MD (US);

Xin Yao, Rockville, MD (US);

Xiaobing Luo, Rockville, MD (US);

Yutian Wei, Rockville, MD (US);

Assignee:

ABELZETA INC., Rockville, MD (US);

Attorney:

LEASON ELLIS LLP

Primary Examiner:

Daniel C Gamett

Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4215 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C12N 5/0636 (2013.01); A61K 2239/13 (2023.05); A61K 2239/21 (2023.05); A61K 2239/22 (2023.05); A61K 2239/29 (2023.05); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01);
Abstract

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

Find Patent Forward Citations

Yao, Yihong. (2025). Bispecific chimeric antigen receptors targeting cd20 and bcma (U.S. Patent No. 12458667). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12458667

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…